Delcath Systems, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gerard J. Michel
- Full Time Employees
- 96
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1633 Broadway New York City NY United States of America 10019
- IPO Date
- May 3, 2018
- CIK
- 0000872912
- Website
- delcath.com
- Similar Companies
- Business
- Delcath Systems, Inc. is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers. The company develops and commercializes proprietary drug and device combination products designed to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure. Its main products include the HEPZATO KIT™ (melphalan for Injection/Hepatic Delivery System), which is FDA-approved for use in the United States, and the CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), which is commercialized in Europe and the United Kingdom. These products are intended for targeted chemotherapy delivery during minimally invasive procedures. Delcath operates primarily in the United States and Europe. Delcath recently reported significant operational progress including the expansion to 25 active U.S. treatment centers and initiation of the global Phase 2 HEPZATO trial focused on liver-dominant metastatic colorectal cancer. They also announced encouraging results from the Phase 2 CHOPIN investigator-initiated trial, showing improved one-year progression-free survival for the combination of CHEMOSAT with immunotherapy agents ipilimumab and nivolumab. The company expects full-year 2025 revenue between $83 million and $85 million, reflecting approximately a 150% increase in treatment volume over 2024. Key strategic highlights include ongoing expansion of treatment centers, strengthening of clinical trial programs, continued adoption of HEPZATO KIT in the U.S., and preparing for broader market penetration with next-generation delivery systems aimed at improving procedural efficiency and standardization. Founded in 1989 and headquartered in New York, Delcath focuses on collaborating with leading oncology treatment centers and academic research institutions such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. The company’s core business includes research, development, manufacturing, and distribution of hepatic delivery systems designed to improve outcomes for patients with liver cancers, including metastatic ocular melanoma and colorectal liver metastases. Recent operational developments include renewed supply agreements for melphalan hydrochloride through 2028 and strategic partnerships to support clinical trial and commercial deployment efforts. Delcath thus positions itself as a leader in liver-directed oncology therapies through innovative product platforms and a growing commercialization footprint, with recent clinical and financial milestones underscoring its growth trajectory and expanding treatment adoption in the oncology community.
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervalued
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
Delcath Systems to Host First Quarter 2026 Earnings Call
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
Contrasting Delcath Systems (NASDAQ:DCTH) & ADB International Group (OTCMKTS:EQUR)
Delcath Systems, Inc. (NASDAQ:DCTH) Receives $22.50 Average PT from Analysts
Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
Delcath: Fundamentals Intact, Despite Share Price Weakness
Delcath Systems Q4 Earnings Call Highlights
Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
Micron Solutions (OTCMKTS:MICR) and Delcath Systems (NASDAQ:DCTH) Critical Review